India Ranbaxy launches its first authorised generic

MUMBAI, July 30 (Reuters) - India's Ranbaxy Laboratories Ltd. (RANB.BO) said on Monday it had launched its first authorised generic drug, Isoptin SR, in the U.S. market, after an agreement with FSC Laboratories.

Isoptin SR is a branded drug used to treat hypertension and the market for its generic form was worth $122.2 million, Ranbaxy, India's largest drug maker by sales, said in a statement.

It said the drug faced limited competition, mainly from two firms. Ranbaxy's shares closed 0.5 percent higher at 376.70 rupees in a flat Mumbai market.

((Reporting by Himangshu Watts, editing by Mark Williams; Reuters Messaging: himangshu.watts.reuters.com@reuters.net +91 22 663 9030)) Keywords: RANBAXY GENERIC/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nBOM287948